Sucampo Puts 40 Reps Behind Rescula Launch As it Seeks Revitalization
This article was originally published in The Pink Sheet Daily
Executive Summary
Tiny Sucampo is betting that its new drug Rescula can make inroads in a heavily generic market because of its clean safety profile and efficacy, but at $99 per 30-day supply WAC, it faces significant headwinds.